{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:45:06Z","timestamp":1762505106327,"version":"3.37.3"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004006","name":"Pfizer Inc.","doi-asserted-by":"publisher","award":["H6D-MC-LVFN"],"award-info":[{"award-number":["H6D-MC-LVFN"]}],"id":[{"id":"10.13039\/501100004006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This U.S. multicenter open-label study used a noninferiority trial design to assess the efficacy of tadalafil 20 mg to treat erectile dysfunction (ED) in the black American and Hispanic groups compared with a reference group of Caucasians. A secondary objective was to demonstrate the efficacy and safety of tadalafil 20 mg in various populations of men with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 1,911 patients with ED were enrolled into eight predefined groups: (1\u20133) Caucasian (Reference group), Black American, or Hispanic patients, \u226465 years of age with no diabetes mellitus or depression; (4) patients with depression, \u226465 years of age, no diabetes; (5) patients with diabetes, \u226465 years of age, no depression; (6) patients &amp;gt;65 years of age, no diabetes or depression; (7) patients who met enrollment criteria but were not included in any other group; and (8) patients with ED due to traumatic spinal cord injury. The study had a 4-week run-in period, followed by a 12-week treatment period with tadalafil taken as needed, up to one dose\/day, prior to sexual activity. Change from baseline to endpoint in the Erectile Function (EF) domain of the International Index of Erectile Function (IIEF) was used to determine noninferiority of groups 2 and 3 from group 1. Secondary efficacy measures included other IIEF domains and Sexual Encounter Profile (SEP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Noninferiority analyses based on the EF domain score showed that tadalafil was as efficacious in the Hispanic and Black American groups as in the Reference group. Patients in each of the eight groups had a significant change from baseline (P &amp;lt; 0.001) in the IIEF EF domain score and positive responses to SEP Questions 1\u20135. The most common treatment-emergent adverse events reported by patients in all eight groups were headache, nasal congestion, dyspepsia, flushing, and back pain.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tadalafil 20 mg was as efficacious in the Hispanic and black American groups as in the Caucasian\/Reference group. Tadalafil was efficacious and well tolerated in each of the groups studied in this trial.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00209.x","type":"journal-article","created":{"date-parts":[[2006,2,15]],"date-time":"2006-02-15T09:42:50Z","timestamp":1139996570000},"page":"492-503","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Tadalafil Across Ethnic Groups and Various Risk Factors in Men with Erectile Dysfunction: Use of a Novel Noninferiority Study Design"],"prefix":"10.1093","volume":"3","author":[{"given":"Abraham","family":"Morgentaler","sequence":"first","affiliation":[{"name":"Harvard Medical School , Brookline , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Barada","sequence":"additional","affiliation":[{"name":"Upstate Urology Albany Center for Sexual Health , Albany , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Niederberger","sequence":"additional","affiliation":[{"name":"University of Illinois Medical Center , Chicago , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Donatucci","sequence":"additional","affiliation":[{"name":"Duke University Medical Center , Durham , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen S.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanni","family":"Natanegara","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjeev","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Wong","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Eli Lilly and Company , Indianapolis , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,5,1]]},"reference":[{"key":"2024032600201865400_bib1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1056\/NEJM200006153422407","article-title":"Erectile dysfunction","volume":"342","author":"Lue","year":"2000","journal-title":"N Engl J Med"},{"key":"2024032600201865400_bib2","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1001\/jama.291.24.2994","article-title":"Clinical crossroads: A 66-year-old man with sexual dysfunction","volume":"291","author":"Morgentaler","year":"2004","journal-title":"JAMA"},{"key":"2024032600201865400_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3810\/pgm.2002.10.1331","article-title":"Hypertension-related disease in African Americans. Factors underlying disparities in illness and its outcome","volume":"112","author":"Sowers","year":"2002","journal-title":"Postgrad Med"},{"key":"2024032600201865400_bib4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/oxfordjournals.aje.a009957","article-title":"Risk factors for stroke in blacks: A critical review","volume":"150","author":"Gillum","year":"1999","journal-title":"Am J Epidemiol"},{"key":"2024032600201865400_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.21.1.83","article-title":"Levels of control of hypertension in Mexican-Americans and non-Hispanic whites","volume":"21","author":"Haffner","year":"1993","journal-title":"Hypertension"},{"key":"2024032600201865400_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/oxfordjournals.aje.a115517","article-title":"Risk factors for cardiovascular mortality in Mexican-Americans and non-Hispanic whites","volume":"131","author":"Mitchell","year":"1990","journal-title":"Am J Epidemiol"},{"key":"2024032600201865400_bib7","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1038\/ng1437","article-title":"Will tomorrow's medicines work for everyone?","volume":"36","author":"Tate","year":"2004","journal-title":"Nat Genet"},{"key":"2024032600201865400_bib8","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJM200105033441802","article-title":"Lesser response to angiotensin-converting enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction","volume":"344","author":"Exner","year":"2001","journal-title":"N Engl J Med"},{"year":"2006","author":"Tadalafil","key":"2024032600201865400_bib9"},{"key":"2024032600201865400_bib10","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"2024032600201865400_bib11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2004.04819.x","article-title":"The efficacy and safety of tadalafil: An update","volume":"93","author":"Carson","year":"2004","journal-title":"BJU Int"},{"issue":"2B","key":"2024032600201865400_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0090-4295(02)01687-4","article-title":"The efficacy of sildenafil citrate (Viagra\u00ae) in clinical subpopulations: An update","volume":"60","author":"Carson","year":"2002","journal-title":"Urology"},{"key":"2024032600201865400_bib13","first-page":"240","article-title":"Viagra (sildenafil citrate) efficacy and tolerability in 25 double-blind, placebo-controlled, clinical trials in men with erectile dysfunction","volume":"12","author":"Price","year":"2001","journal-title":"Eur J Intern Med"},{"year":"2006","author":"Vardenafil","key":"2024032600201865400_bib14"},{"key":"2024032600201865400_bib15","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/j.1939-4640.2002.tb02332.x","article-title":"Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial","volume":"23","author":"Hellstrom","year":"2002","journal-title":"J Androl"},{"key":"2024032600201865400_bib16","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1185\/030079904X4392","article-title":"Rationale for a non-inferiority clinical trial design focused on subpopulations","volume":"20","author":"Kulkarni","year":"2004","journal-title":"Curr Med Res Opin"},{"author":"Points to consider on the choice of non-inferiority margin [online]","key":"2024032600201865400_bib17"},{"key":"2024032600201865400_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/009286159903300424","article-title":"Design issues in noninferiority\/equivalence trials","volume":"33","author":"Hwang","year":"1999","journal-title":"Drug Inform J"},{"key":"2024032600201865400_bib19","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1097\/00000542-200006000-00042","article-title":"Current issues in clinical trial design: Superiority versus equivalency studies","volume":"92","author":"Landow","year":"2000","journal-title":"Anesthesiology"},{"key":"2024032600201865400_bib20","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/sim.1425","article-title":"Non-inferiority trials design concepts and issues\u2014The encounters of academic consultants in statistics","volume":"22","author":"Agostino","year":"2003","journal-title":"Stat Med"},{"key":"2024032600201865400_bib21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/01.ju.0000063377.12281.57","article-title":"Deciphering erectile dysfunction drug trials","volume":"170","author":"Mulhall","year":"2003","journal-title":"J Urol"},{"key":"2024032600201865400_bib22","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0090-4295(02)01689-8","article-title":"Efficacy and safety of sildenafil citrate (Viagra\u00ae) in Black and Hispanic American men","volume":"60","author":"Young","year":"2002","journal-title":"Urology"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515313540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515313540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/3\/492\/47743577\/jsm_3_3_492.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/3\/3\/492\/47743577\/jsm_3_3_492.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:13:59Z","timestamp":1711415639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/3\/3\/492\/6883760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,5,1]]},"published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00209.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"type":"electronic","value":"1743-6109"},{"type":"print","value":"1743-6095"}],"subject":[],"published-other":{"date-parts":[[2006,5]]},"published":{"date-parts":[[2006,5,1]]}}}